搜尋
Jazz Pharmaceuticals PLC
JAZZ添加自選
252.860USD
-5.520-2.14%
收盤 07-31 16:00（美東）報價延遲15分鐘
15.53B總市值
613.23本益比TTM
關於 Jazz Pharmaceuticals PLC 公司
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC簡介
公司代碼JAZZ
公司名稱Jazz Pharmaceuticals PLC
上市日期Jan 18, 2012
CEOGala (Renee D)
員工數量2800
證券類型Ordinary Share
年結日Jan 18
公司地址Fifth Floor, Waterloo Exchange
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Ireland
郵編- -
電話35316347800
網址https://www.jazzpharma.com/
公司代碼JAZZ
上市日期Jan 18, 2012
CEOGala (Renee D)
Jazz Pharmaceuticals PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
常見問題
Jazz Pharmaceuticals PLC的前五大股東是誰？
Jazz Pharmaceuticals PLC的前五大股東如下：Mr. Seamus C. Mulligan
有多少機構持有Jazz Pharmaceuticals PLC(JAZZ)的股份？
截至2026Q1，共有1229家機構持有Jazz Pharmaceuticals PLC的股份，合計持有的股份價值約為70.31M，占公司總股份的112.06% 。與2025Q4相比，機構持股有所增加，增幅為-754072.00。
哪個業務部門對Jazz Pharmaceuticals PLC的收入貢獻最大？
在2026Q1，Xywav業務部門對Jazz Pharmaceuticals PLC的收入貢獻最大，創收1.66B，占總收入的38.83% 。